Posted by shellson2 on 26th of Dec 2024 at 12:04 pm
I try to follow as much biotech as possible...this is a lottery
play, with some recent momentum. A real cheapy that may have
its day in coming year. Check it out.
Posted by shellson2 on 26th of Dec 2024 at 12:53 pm
some color on SENS.
GERMANTOWN, Md., Dec. 09, 2024 (GLOBE NEWSWIRE) --
Senseonics Holdings, Inc. (NYSE:
SENS), a
medical technology company focused on the development and
manufacturing of long-term, implantable continuous glucose
monitoring (CGM) systems for people with diabetes, today provided
commercial updates related to the Eversense® 365 launch.
Eversense 365 Commercial Launch Update
Launched Eversense 365 in October with global commercial
partner Ascensia Diabetes Care and began shipping product in
November
Seeing strong interest in Eversense 365, as evidenced by the
following early launch performance indicators:
Direct-to-Consumer (DTC) leads in each of October and November
were more than double the number of leads in pre-launch months
New patient shipments in November were the highest compared to
any month since inception of the Ascensia partnership
Since launch, Eversense 365 has already shown a 42% increase in
the number of providers prescribing Eversense and a 69% increase in
prescriptions from top prescribers compared to the pre-launch rate
in 2024
One-third of Eversense 365 prescribers are new first-time
Eversense prescribers
The number of patients switching to Eversense monthly from
competitive CGMs has increased 47% since Eversense 365 launch
Remain on-target to achieve annual growth of approximately 50%
in patient installed base at the end of 2024 as compared with
2023
Reiterated full-year 2024 global net revenue guidance of
approximately $22 million
Posted by shellson2 on 12th of Feb 2025 at 11:03 am
SENS--EU compliance may be next trigger for
stock
Eversense 365 is the world's first and only one
year CGM, which was approved by the United States (US) Food and
Drug Administration in September of 2024 and launched across the
country in October of the same year.
The Eversense 365 CE Mark submission was prepared
in compliance with the EU Medical Device Regulation (MDR) and,
upon approval, would enable the commercialization of Eversense 365
in European Union (EU) member countries by Senseonics' commercial
partner, Ascensia Diabetes Care. Following CE Mark approval
in Europe, the Company plans to distribute the Eversense 365
System in Germany, Italy, Spain (including Andorra), Poland,
Switzerland and Sweden.
"Completing the CE Mark submission for Eversense
365 brings us a step closer to improving lives and health outcomes
for patients in Europe. Given the success we have had to date with
the US launch of Eversense 365 by our partner, Ascensia, we look
forward to the opportunity to offer a ‘once a year' solution for
glucose control to the millions of people living with diabetes in
the European Union," said Tim Goodnow, PhD, President and Chief
Executive Officer of Senseonics.
I try to follow as
Posted by shellson2 on 26th of Dec 2024 at 12:04 pm
I try to follow as much biotech as possible...this is a lottery play, with some recent momentum. A real cheapy that may have its day in coming year. Check it out.
oops. SENS is ticker
Posted by shellson2 on 26th of Dec 2024 at 12:04 pm
oops. SENS is ticker
still
Posted by ruidoso on 27th of Dec 2024 at 09:18 am
still
some color on SENS. GERMANTOWN, Md.,
Posted by shellson2 on 26th of Dec 2024 at 12:53 pm
some color on SENS.
GERMANTOWN, Md., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today provided commercial updates related to the Eversense® 365 launch.
Eversense 365 Commercial Launch Update
benzinga.com
Senseonics Holdings (AMEX:SENS) Stock Quotes, Forecast and News Summary - Benzinga
Senseonics Holdings Stock (AMEX: SENS) stock price, news, charts, stock research, profile.
SENS--penny stock on the move.
Posted by shellson2 on 10th of Jan 2025 at 10:40 am
SENS--penny stock on the move. One to monitor
SENS--(penny stock mentioned from 1/10).
Posted by shellson2 on 16th of Jan 2025 at 10:25 am
SENS--(penny stock mentioned from 1/10). Now at .78, up 10% today on above avg Vol. Keep on radar.
SENS--.93 pre-market.
Posted by shellson2 on 17th of Jan 2025 at 09:24 am
SENS--.93 pre-market.
SENS-- See my previous posts. Now at
Posted by shellson2 on 24th of Jan 2025 at 09:46 am
SENS--
See my previous posts.
Now at 1.08, heavy volume.
SENS-- New 52wk today, vol is
Posted by shellson2 on 12th of Feb 2025 at 10:58 am
SENS--
New 52wk today, vol is above average. Their next business update could be very meaningful. Will dig for that info.
SENS--EU compliance may be next
Posted by shellson2 on 12th of Feb 2025 at 11:03 am
SENS--EU compliance may be next trigger for stock
Eversense 365 is the world's first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of the same year.
The Eversense 365 CE Mark submission was prepared in compliance with the EU Medical Device Regulation (MDR) and, upon approval, would enable the commercialization of Eversense 365 in European Union (EU) member countries by Senseonics' commercial partner, Ascensia Diabetes Care. Following CE Mark approval in Europe, the Company plans to distribute the Eversense 365 System in Germany, Italy, Spain (including Andorra), Poland, Switzerland and Sweden.
"Completing the CE Mark submission for Eversense 365 brings us a step closer to improving lives and health outcomes for patients in Europe. Given the success we have had to date with the US launch of Eversense 365 by our partner, Ascensia, we look forward to the opportunity to offer a ‘once a year' solution for glucose control to the millions of people living with diabetes in the European Union," said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics.
Senseonics Holdings, Inc. Schedules Fourth
Posted by shellson2 on 13th of Feb 2025 at 11:56 am
Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for March 3, 2025 at 4:30 P.M. Eastern Time
Up 15%, way above volume
Posted by shellson2 on 13th of Feb 2025 at 09:44 am
Up 15%, way above volume
Now +24%
Posted by shellson2 on 16th of Jan 2025 at 01:45 pm
Now +24%
The guy that buys everything
Posted by mastermind on 16th of Jan 2025 at 02:22 pm
The guy that buys everything didn't take this one.
holy smokes!
Posted by morton7 on 16th of Jan 2025 at 01:57 pm
holy smokes!
Ramping now
Posted by shellson2 on 10th of Jan 2025 at 03:42 pm
Ramping now
Nice spotting early on today
Posted by steve on 10th of Jan 2025 at 03:46 pm
Nice spotting early on today shellson
SENS Looks like we are
Posted by srusso1 on 10th of Jan 2025 at 12:54 pm
SENS Looks like we are getting lucky today on this one Thanks
Has halved the days losses
Posted by shellson2 on 13th of Jan 2025 at 11:04 am
Has halved the days losses thus far. Monitoring red to green potential
Green. Damn that was quick
Posted by shellson2 on 13th of Jan 2025 at 11:08 am
Green. Damn that was quick
Out of this now +8%
Posted by srusso1 on 10th of Jan 2025 at 01:38 pm
Out of this now +8%
Thankyou
Posted by ruidoso on 26th of Dec 2024 at 02:07 pm
Thankyou